Jinlian Zhu, Jie Chen, Wei Liu, Junling Zhang, Yulan Gu
{"title":"MET D1228N突变是伴有MET Y1003H突变的NSCLC患者克唑替尼耐药的后天潜在机制","authors":"Jinlian Zhu, Jie Chen, Wei Liu, Junling Zhang, Yulan Gu","doi":"10.2147/LCTT.S467584","DOIUrl":null,"url":null,"abstract":"<p><p>Mesenchymal-epithelial transition (<i>MET</i>) gene has been identified as a promising target for treatments. However, different sites of the <i>MET</i> mutation show different effects to MET inhibition. Here, we reported a non-small cell lung cancer (NSCLC) patient harboring <i>MET Y1003H</i> mutation who achieved a durable partial response to crizotinib with a PFS of 22.4 months. Furthermore, we report for the first time the identification of <i>MET D1228N</i> as a possible mechanism of acquired resistance to crizotinib in a patient with <i>MET Y1003H</i> mutation during disease progression.</p>","PeriodicalId":18066,"journal":{"name":"Lung Cancer: Targets and Therapy","volume":"15 ","pages":"123-128"},"PeriodicalIF":5.1000,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11365520/pdf/","citationCount":"0","resultStr":"{\"title\":\"Mutation of <i>MET D1228N</i> as an Acquired Potential Mechanism of Crizotinib Resistance in NSCLC with <i>MET Y1003H</i> Mutation.\",\"authors\":\"Jinlian Zhu, Jie Chen, Wei Liu, Junling Zhang, Yulan Gu\",\"doi\":\"10.2147/LCTT.S467584\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Mesenchymal-epithelial transition (<i>MET</i>) gene has been identified as a promising target for treatments. However, different sites of the <i>MET</i> mutation show different effects to MET inhibition. Here, we reported a non-small cell lung cancer (NSCLC) patient harboring <i>MET Y1003H</i> mutation who achieved a durable partial response to crizotinib with a PFS of 22.4 months. Furthermore, we report for the first time the identification of <i>MET D1228N</i> as a possible mechanism of acquired resistance to crizotinib in a patient with <i>MET Y1003H</i> mutation during disease progression.</p>\",\"PeriodicalId\":18066,\"journal\":{\"name\":\"Lung Cancer: Targets and Therapy\",\"volume\":\"15 \",\"pages\":\"123-128\"},\"PeriodicalIF\":5.1000,\"publicationDate\":\"2024-08-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11365520/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Lung Cancer: Targets and Therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2147/LCTT.S467584\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lung Cancer: Targets and Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/LCTT.S467584","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
Mutation of MET D1228N as an Acquired Potential Mechanism of Crizotinib Resistance in NSCLC with MET Y1003H Mutation.
Mesenchymal-epithelial transition (MET) gene has been identified as a promising target for treatments. However, different sites of the MET mutation show different effects to MET inhibition. Here, we reported a non-small cell lung cancer (NSCLC) patient harboring MET Y1003H mutation who achieved a durable partial response to crizotinib with a PFS of 22.4 months. Furthermore, we report for the first time the identification of MET D1228N as a possible mechanism of acquired resistance to crizotinib in a patient with MET Y1003H mutation during disease progression.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
